ClinConnect ClinConnect Logo
Search / Trial NCT01195870

Assessment of Patient Use of a New Device: RebiSmart

Launched by MERCK KGAA, DARMSTADT, GERMANY · Sep 3, 2010

Trial Information

Current as of July 01, 2025

Completed

Keywords

Multiple Sclerosis Rebif Interferon Beta 1a

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have relapsing remitting multiple sclerosis
  • Between 18 to 65 years old inclusive
  • Have been prescribed Rebif for the first time but not yet started treatment
  • Rebismart as chosen device
  • Be under review by MS nurse
  • Having given written informed consent to participate in the study
  • Exclusion Criteria:
  • Injections of Rebif given by someone other than the patient
  • Patients unable to use the Rebismart device due to visual or physical impairment
  • Patients unwilling to give informed consent
  • Contra-indications to Rebif as defined in the Summary of Product Characteristics (SPC).
  • Allergy to the antipyretic analgesics that will be advised as prophylaxis for flu-like symptoms

About Merck Kgaa, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading global science and technology company, specializing in healthcare, life sciences, and performance materials. With a rich history dating back to 1668, Merck KGaA is committed to advancing innovative solutions that improve the quality of life for patients and drive scientific discovery. The company invests significantly in research and development to bring cutting-edge therapies to market, focusing on areas such as oncology, immunology, and neurology. As a dedicated clinical trial sponsor, Merck KGaA collaborates with healthcare professionals and institutions worldwide to conduct rigorous trials that ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and foster global health advancements.

Locations

Patients applied

0 patients applied

Trial Officials

Dr Gillian L Shepherd, MD, MRCP

Study Director

Merck Serono Limited, UK

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials